The global indapamide market is estimated to grow significantly at a CAGR of over 2.0% during the forecast period. A significant rise in the incidences of high blood pressure (hypertension) and congestive heart failure is primarily contributing to the growth of the market. High blood pressure affects approximately a third of the adult population across the globe and is the most common cause of CVD-related mortalities. As per the data published by the American Health Association (AHA) in January 2018, 103 million US adults were suffering from high blood pressure, which is nearly half of all adults in the US.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/indapamide-market
The global indapamide market is segmented on the basis of product and application. Based on the product, the market is bifurcated into 1.25 mg indapamide and 2.5 mg indapamide. Among these, the market for 1.25 mg medicine held a significant market share owing to the extensive application of the drug in treating high blood pressure or hypertension. Based on the application, the market is segmented into high blood pressure, heart failure, and others. The high blood pressure segment is projected to have a significant share in the market. Growing incidence of hypertension is contributing to the segmental growth as indapamide drugs are significantly used to treat hypertension while reducing the risk of developing serious heart conditions.
Geographically, the study of the global indapamide market covers the analysis of four major regions including North America (the US and Canada), Europe (UK, Germany, Italy, Spain, France, and Rest of Europe), Asia-Pacific (China, Japan, India, and Rest of Asia-Pacific), and the Rest of the World. The companies which are contributing to the growth of the global indapamide market include ANI Pharmaceuticals, Inc., Apotex Inc., Krka Group, Glenmark Pharmaceuticals Ltd, Les Laboratoires Servier, SAS, Sandoz International Gmbh (A Novartis Division), Taj Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., and Teva Pharmaceutical Industries Ltd. Various growth strategies are adopted by the market players to expand their market share and gain a competitive advantage. For instance, in January 2020, ANI Pharmaceuticals, Inc., acquired the US portfolio of 23 generic products from Amrigen Pharmaceuticals Ltd.
Indapamide Market- Segmentation
By Product
- 25 MG
- 5 MG
By Application
- High Blood Pressure
- Heart Failure
- Others
A full report of Indapamide Market is available at: https://www.omrglobal.com/industry-reports/indapamide-market
